ANIX - Anixa Bio shares surge 35% on European patent for ovarian cancer vaccine technology

The European Patent Office has issued the first European patent for Anixa Biosciences' (ANIX) novel ovarian cancer vaccine technology. The patent is titled, "Ovarian Cancer Vaccines".This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.   "Our vaccine targets the AMHR2-ED and trains the immune system to destroy these cancer cells as they arise," said Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute.Recently, the company nabbed European patent for CAR-T cancer treatment technology.ANIX shares soar 35% premarket, trading at $6.92.

For further details see:

Anixa Bio shares surge 35% on European patent for ovarian cancer vaccine technology